Skip to main content
. 2021 Mar 19;12:9. doi: 10.1007/s12672-021-00404-x

Fig. 1.

Fig. 1

Flow chart showing the patients included and excluded in this study. mPPGL, metastatic pheochromocytoma/paraganglioma; non-mPPGL, non-metastatic pheochromocytoma/paraganglioma. *Three of 14 developed metastatic disease more than one year after study entry